The two patients whose carcinomas harbored BRAF V600E mutations, for example, would not be identified as candidates for EGFR-directed therapy had their samples been collected with the longer one hour cold ischemic interval that is not only seen in clinical pathology areas, but is also deemed acceptable in a current cancer biomarker analysis guideline. This evidence concerns the gene BRAF and carcinoma.